Chemotherapy doses and survival in older lung cancer patients
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how lowering chemotherapy doses affects survival in older patients with advanced lung cancer who do not have certain genetic mutations. It may help doctors understand the best way to treat this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years or older
- You have stage 4 non-small cell lung cancer
- Your cancer does not have certain gene changes (EGFR, ALK, or ROS1)
- You have received at least one round of first-line chemotherapy
- You have not received immunotherapy or targeted therapy as your first treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This trial tests a new way to treat non-small cell lung cancer in people aged 70 or older. You will receive oral chemotherapy (paclitaxel) with immunotherapy and focused radiation (SBRT) before surgery, hoping to shrink the tumor and improve outcomes.
This study tests a milder chemotherapy combined with an immunotherapy drug (anti-PD-1) as the first treatment for advanced lung cancer in older or frailer adults. It aims to see if this approach works better with fewer side effects.
This trial compares chemotherapy combined with immunotherapy to immunotherapy alone for adults 70 and older with advanced non-small cell lung cancer that has a specific protein level (PD-L1 1-49%). It aims to find which treatment works better for this group.
This trial is testing a combination of an oral chemotherapy pill (vinorelbine) and an immunotherapy drug (PD-1 inhibitor) for people aged 65 and older with advanced non-small cell lung cancer who have not had treatment before. The goal is to see if this approach can help control the cancer with fewer side effects.
This trial tests a combination of chemotherapy and immunotherapy for people 65 or older with metastatic non-small cell lung cancer that has not been treated before and expresses PD-L1. It aims to see if this treatment can help control the cancer.
Hear when a new Non Small Cell Lung Carcinoma NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.